T-cell and NK-cell Lymphoid Proliferations and Lymphomas
T-cell and NK-cell lymphoid proliferations and lymphomas encompass a diverse range of malignancies arising from the immune system. The intricacies involved in accurately diagnosing and devising effective therapeutic approaches for these diseases present formidable challenges. At our company, we pride ourselves on being at the forefront of drug and therapy development services for T-cell and NK-cell lymphoid proliferations and lymphomas.
Overview of T-cell and NK-cell Lymphoid Proliferations and Lymphomas
T-cell and NK-cell lymphoid proliferations and lymphomas present as a heterogeneous array of hematological malignancies, marked by the unrestricted growth of T-cell or NK-cell lymphocytes. The development and progression of these conditions involve a multifaceted interplay between genetic and environmental factors, culminating in their pathogenesis. Aberrations in T-cell receptor signaling pathways, such as mutations in genes encoding T-cell receptor subunits or downstream signaling molecules, contribute to the dysregulation of lymphocyte proliferation and survival. Additionally, alterations in cytokine signaling and immune evasion mechanisms further promote disease progression.
Fig.1 JAK-STAT signaling pathway and immune response evasion disturbances in Extranodal NK/T cell lymphoma (ENKTCL). (Montes-Mojarro, Ivonne A., et al., 2021)Classification of T-cell and NK-cell Lymphoid Proliferations and Lymphomas
| T-cell and NK-cell lymphoid proliferations and lymphomas | ||
|---|---|---|
| Tumor-like lesions with T-cell predominance | ||
| Precursor T-cell neoplasms | ||
| Mature T-cell and NK-cell neoplasms | ||
| mature T-cell and NK-cell leukaemias | ||
| T-prolymphocytic leukemia | T-large granular lymphocytic leukemia | NK-large granular lymphocytic leukemia |
| adult T-cell leukemia/lymphoma | Sézary syndrome | aggressive NK-cell leukemia |
| primary cutaneous T-cell lymphoid proliferations and lymphomas | ||
| intestinal T-cell and NK-cell lymphoid proliferations and lymphomas | ||
| hepatosplenic T-cell lymphoma | ||
| anaplastic large cell lymphoma | ||
| nodal T-follicular helper (TFH) cell lymphoma | ||
| nodal TFH cell lymphoma, angioimmunoblastic-type | nodal TFH cell lymphoma, follicular-type | nodal TFH cell lymphoma, NOS |
| peripheral T-cell lymphoma, NOS | ||
| EBV-positive NK-cell and T-cell lymphomas | ||
| EBV-positive T-cell and NK-cell lymphoid proliferations and lymphomas of childhood | ||
Therapy Development of T-cell and NK-cell Lymphoid Proliferations and Lymphomas
Immune Checkpoint Inhibitor
Immune checkpoint inhibitors, such as anti-PD1 antibodies pembrolizumab, nivolumab, and sintilimab, have shown remarkable efficacy in relapsed/refractory NK/T-cell lymphomas. These inhibitors target the PD1/PD-L1 axis, restoring antitumor immune responses and leading to significant therapeutics responses.
Antibody-based Therapy
Antibody-based therapies present a focused strategy in the management of T-cell and NK-cell lymphoid proliferations and lymphomas. Brentuximab vedotin (BV), an antibody conjugate targeting CD30, has demonstrated effectiveness in cases that have relapsed or have been refractory to previous therapies.
Histone Deacetylase Inhibitor
Histone deacetylase inhibitors, such as chidamide, have demonstrated promising results in relapsed/refractory NK/T-cell lymphomas. These inhibitors target the aberrant epigenetic modifications associated with lymphoma development.
Adoptive Cellular Therapy
Adoptive cellular therapy, specifically the utilization of autologous cytotoxic T-cells (CTL) that target Epstein-Barr virus (EBV), has exhibited promising outcomes in relapsed NK/T-cell lymphomas. This innovative approach capitalizes on the immune system, enabling the precise targeting of malignant cells.
Our Services
Targeted therapies, such as immune checkpoint inhibitors and histone deacetylase inhibitors, provide a more individualized and precise strategy. These therapies aim to disrupt the disease pathways and restore normal immune responses specifically. Our Company is dedicated to advancing the development of diagnostics and targeted therapies for T-cell and NK-cell lymphoid proliferations and lymphomas.
Our Therapy Development Platforms
With a hallmark of combining cutting-edge research with state-of-the-art technology, our company offers comprehensive animal model development services. We focus on developing animal models for preclinical research that accurately reproduce T-cell and NK-cell lymphoid proliferation and lymphoma. At the same time, we have different animal species to meet your needs for pharmacokinetic analysis and drug safety evaluation.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Montes-Mojarro, Ivonne A., Falko Fend, and Leticia Quintanilla-Martinez. "EBV and the Pathogenesis of NK/T Cell Lymphoma." Cancers 13.6 (2021): 1414.
- Tse, Eric, et al. "How we treat NK/T-cell lymphomas." Journal of Hematology & Oncology 15.1 (2022): 74.
- Wang, Hua, et al. "NK-/T-cell lymphomas." Leukemia 35.9 (2021): 2460-2468.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.